Host-directed drug targeting of factors hijacked by pathogens

Science Signaling

Volumn 1, Issue 29, 2008, Pages

  Schwegmann, Anita ^a   Brombacher, Frank ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANIMAL; BACTERIAL INFECTION; BIOLOGICAL MODEL; COMMUNICABLE DISEASE; DRUG DELIVERY SYSTEM; GENETIC PROCEDURES; GENOME; HUMAN; INFECTION; METHODOLOGY; MICROBIOLOGY; PARASITOLOGY; PHARMACOGENETICS; REVIEW; SIGNAL TRANSDUCTION; VIROLOGY; VIRULENCE; VIRUS INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; COMMUNICABLE DISEASES; DRUG DELIVERY SYSTEMS; GENETIC TECHNIQUES; GENOME; HUMANS; INFECTION; MODELS, BIOLOGICAL; PHARMACOGENETICS; SIGNAL TRANSDUCTION; VIRULENCE; VIRUS DISEASES;

EID: 48849094355     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.129re8     Document Type: Review

References (124)

1. C. Walsh, Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775-781 (2000).
2. L. E. Cowen, The evolution of fungal drug resistance: Modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol. 6, 187-198 (2008).
3. L. Cegelski, G. R. Marshall, G. R. Eldridge, S. J. Hultgren, The biology and future prospects of antivirulence therapies. Nat. Rev. Microbiol. 6, 17-27 (2008).
4. A. L. Brass, D. M. Dykxhoorn, Y. Benita, N. Yan, A. Engelman, R. J. Xavier, J. Lieberman, S. J. Elledge, Identification of host proteins required for HIV infection through a functional genomic screen. Science 319, 921-926 (2008).
5. D. G. Nguyen, H. Yin, Y. Zhou, K. C. Wolff, K. L. Kuhen, J. S. Caldwell, Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening. Virology 362, 16-25 (2007).
6. J. Fink, F. Gu, L. Ling, T. Tolfvenstam, F. Olfat, K. C. Chin, P. Aw, J. George, V. A. Kuznetsov, M. Schreiber, S. G. Vasudevan, M. L. Hibberd, Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl. Trop. Dis. 1, e86 (2007).
7. L. Supekova, F. Supek, J. Lee, S. Chen, N. Gray, J. P. Pezacki, A. Schlapbach, P. G. Schultz, Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J. Biol. Chem. 283, 29-36 (2008).
8. X. R. Ding, J. Yang, D. C. Sun, S. K. Lou, S. Q. Wang, Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs. Pharmacogenomics J. 8, 61-70 (2008).
9. T. I. Ng, H. Mo, T. Pilot-Matias, Y. He, G. Koev, P. Krishnan, R. Mondal, R. Pithawalla, W. He, T. Dekhtyar, J. Packer, M. Schurdak, A. Molla, Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 45, 1413-1421 (2007).
10. I. Derre, M. Pypaert, A. Dautry-Varsat, H. Agaisse, RNAi screen in Drosophila cells reveals the involvement of the Tom complex in Chlamydia infection. PLoS Pathog. 3, 1446-1458 (2007).
11. H. Agaisse, L. S. Burrack, J. A. Philips, E. J. Rubin, N. Perrimon, D. E. Higgins, Genomewide RNAi screen for host factors required for intracellular bacterial infection. Science 309, 1248-1251 (2005).
12. L. W. Cheng, J. P. Viala, N. Stuurman, U. Wiedemann, R. D. Vale, D. A. Portnoy, Use of RNA interference in Drosophila S2 cells to identify host pathways controlling compartmentalization of an intracellular pathogen. Proc. Natl. Acad. Sci. U.S.A. 102, 13646-13651 (2005).
13. J. S. Ayres, N. Freitag, D. S. Schneider, Identification of Drosophila Mutants Altering Defense of and Endurance to Listeria monocytogenes Infection. Genetics 178, 1807-1815 (2008).
14. R. Zhou, N. Silverman, M. Hong, D. S. Liao, Y. Chung, Z. J. Chen, T. Maniatis, The role of ubiquitination in Drosophila innate immunity. J. Biol. Chem. 280, 34048-34055 (2005).
15. C. Kuijl, N. D. Savage, M. Marsman, A. W. Tuin, L. Janssen, D. A. Egan, M. Ketema, R. van den Nieuwendijk, S. J. van den Eeden, A. Geluk, A. Poot, G. van der Marel, R. L. Beijersbergen, H. Overkleeft, T. H. Ottenhoff, J. Neefjes, Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 450, 725-730 (2007).
16. J. Pizarro-Cerda, P. Cossart, Subversion of phosphoinositide metabolism by intracellular bacterial pathogens. Nat. Cell Biol. 6, 1026-1033 (2004).
17. L. A. Knodler, B. B. Finlay, O. Steele-Mortimer, The Salmonella effector protein SopB protects epithelial cells from apoptosis by sustained activation of Akt. J. Biol. Chem. 280, 9058-9064 (2005).
18. J. Gosling, F. S. Monteclaro, R. E. Atchison, H. Arai, C. L. Tsou, M. A. Goldsmith, I. F. Charo, Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc. Natl. Acad. Sci. U.S.A. 94, 5061-5066 (1997).
19. E. Boucrot, T. Henry, J. P. Borg, J. P. Gorvel, S. Meresse, The intracellular fate of Salmonella depends on the recruitment of kinesin. Science 308, 1174-1178 (2005).
20. J. E. Cameron, Q. Yin, C. Fewell, M. Lacey, J. McBride, X. Wang, Z. Lin, B. C. Schaefer, E. K. Flemington, Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J. Virol. 82, 1946-1958 (2008).
21. M. Coiras, E. Camafeita, M. R. Lopez-Huertas, E. Calvo, J. A. Lopez, J. Alcami, Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. Proteomics 8, 852-873 (2008).
22. K. Hilpert, R. E. Hancock, Use of luminescent bacteria for rapid screening and characterization of short cationic antimicrobial peptides synthesized on cellulose using peptide array technology. Nat. Protocols 2, 1652-1660 (2007).
23. A. Honda, Role of host protein Ebp1 in influenza virus growth: Intracellular localization of Ebp1 in virus-infected and uninfected cells. J. Biotechnol. 133, 208-212 (2008).
24. A. Honda, T. Okamoto, A. Ishihama, Host factor Ebp1: Selective inhibitor of influenza virus transcriptase. Genes Cells 12, 133-142 (2007).
25. R. M. O'Connell, D. S. Rao, A. A. Chaudhuri, M. P. Boldin, K. D. Taganov, J. Nicoll, R. L. Paquette, D. Baltimore, Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp. Med. 205, 585-594 (2008).
26. K. D. Taganov, M. P. Boldin, D. Baltimore, MicroRNAs and immunity: Tiny players in a big field. Immunity 26, 133-137 (2007).
27. J. Doorbar, H. Griffin, Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin. Biol. Ther. 7, 677-689 (2007).
28. C. H. Swan, B. Buhler, P. Steinberger, M. P. Tschan, C. F. Barbas III, B. E. Torbett, T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther. 13, 1480-1492 (2006).
29. R. Zemel, Y. Berdichevsky, L. Bachmatov, I. Benhar, R. Tur-Kaspa, Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies. J. Hepatol. 40, 1000-1007 (2004).
30. J. Manikandan, P. N. Pushparaj, A. J. Melendez, Protein i: Interference at protein level by intrabodies. Front. Biosci. 12, 1344-1352 (2007).
31. T. Boldicke, Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J. Cell. Mol. Med. 11, 54-70 (2007).
32. S. E. Wurster, L. J. Maher III, Selection and characterization of anti-NF-kappaB p65 RNA aptamers. RNA 14, 1037-1047 (2008).
33. Y. Wu, G. Zhang, Y. Li, Y. Jin, R. Dale, L. Q. Sun, M. Wang, Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene. Biochem. Biophys. Res. Commun. 365, 369-374 (2008).
34. A. Trahtenherts, M. Gal-Tanamy, R. Zemel, L. Bachmatov, S. Loewenstein, R. Tur-Kaspa, I. Benhar, Inhibition of hepatitis C virus RNA replicons by peptide aptamers. Antiviral Res. 77, 195-205 (2008).
35. G. Kaur, I. Roy, Therapeutic applications of aptamers. Expert Opin. Investig. Drugs 17, 43-60 (2008).
36. P. Bellecave, C. Cazenave, J. Rumi, C. Staedel, O. Cosnefroy, M. L. Andreola, M. Ventura, L. Tarrago-Litvak, T. Astier-Gin, Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: Mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells. Antimicrob. Agents Chemother. 52, 2097-2110 (2008).
37. F. Chen, J. Zhou, F. Luo, A. B. Mohammed, X. L. Zhang, Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochem. Biophys. Res. Commun. 357, 743-748 (2007).
38. T. Mairal, V. C. Ozalp, P. Lozano Sanchez, M. Mir, I. Katakis, C. K. O'Sullivan, Aptamers: Molecular tools for analytical applications. Anal. Bioanal. Chem. 390, 989-1007 (2008).
39. C. I. Liu, G. Y. Liu, Y. Song, F. Yin, M. E. Hensler, W. Y. Jeng, V. Nizet, A. H. Wang, E. Oldfield, A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319, 1391-1394 (2008).
40. R. G. Panchal, G. Ruthel, K. C. Brittingham, D. Lane, T. A. Kenny, R. Gussio, J. S. Lazo, S. Bavari, Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis. Chem. Biol. 14, 245-255 (2007).
41. P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, M. Perros, Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732 (2005).
42. M. Dean, M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, S. J. O'Brien, Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856-1862 (1996).
43. C. A. Derdeyn, J. M. Decker, J. N. Sfakianos, Z. Zhang, W. A. O'Brien, L. Ratner, G. M. Shaw, E. Hunter, Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75, 8605-8614 (2001).
44. R. Liu, W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, N. R. Landau, Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiplyexposed individuals to HIV-1 infection. Cell 86, 367-377 (1996).
45. M. Samson, F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, M. Parmentier, Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725 (1996).
46. J. A. Este, A. Telenti, HIV entry inhibitors. Lancet 370, 81-88 (2007).
47. G. Fatkenheuer, A. L. Pozniak, M. A. Johnson, A. Plettenberg, S. Staszewski, A. I. Hoepelman, M. S. Saag, F. D. Goebel, J. K. Rockstroh, B. J. Dezube, T. M. Jenkins, C. Medhurst, J. F. Sullivan, C. Ridgway, S. Abel, I. T. James, M. Youle, E. van der Ryst, Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11, 1170-1172 (2005).
48. A. Opar, New HIV drug classes on the horizon. Nat. Rev. Drug Discov. 6, 258-259 (2007).
49. H. Nakata, S. M. Steinberg, Y. Koh, K. Maeda, Y. Takaoka, H. Tamamura, N. Fujii, H. Mitsuya, Potent synergistic anti-HIV effects using combinations of a CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob. Agents Chemother. 52, 2111-2119 (2008).
50. D. Durantel, C. Alotte, F. Zoulim, Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr. Opin. Investig. Drugs 8, 125-129 (2007).
51. P. Kellam, Attacking pathogens through their hosts. Genome Biol. 7, 201 (2006).
52. H. P. Hsieh, J. T. Hsu, Strategies of development of antiviral agents directed against influenza virus replication. Curr. Pharm. Des. 13, 3531-3542 (2007).
53. C. Doerig, L. Meijer, Antimalarial drug discovery: Targeting protein kinases. Expert Opin. Ther. Targets 11, 279-290 (2007).
54. J. M. Goldman, B. J. Druker, Chronic myeloid leukemia: Current treatment options. Blood 98, 2039-2042 (2001).
55. P. M. Reeves, B. Bommarius, S. Lebeis, S. McNulty, J. Christensen, A. Swimm, A. Chahroudi, R. Chavan, M. B. Feinberg, D. Veach, W. Bornmann, M. Sherman, D. Kalman, Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 11, 731-739 (2005).
56. H. Yang, S. K. Kim, M. Kim, P. A. Reche, T. J. Morehead, I. K. Damon, R. M. Welsh, E. L. Reinherz, Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379-387 (2005).
57. S. Ludwig, T. Wolff, C. Ehrhardt, W. J. Wurzer, J. Reinhardt, O. Planz, S. Pleschka, MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 561, 37-43 (2004).
58. S. Pleschka, T. Wolff, C. Ehrhardt, G. Hobom, O. Planz, U. R. Rapp, S. Ludwig, Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 3, 301-305 (2001).
59. S. Ludwig, X. Wang, C. Ehrhardt, H. Zheng, N. Donelan, O. Planz, S. Pleschka, A. Garcia-Sastre, G. Heins, T. Wolff, The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J. Virol. 76, 11166-11171 (2002).
60. C. Lindenthal, N. Weich, Y. S. Chia, V. Heussler, M. Q. Klinkert, The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites. Parasitology 131, 37-44 (2005).
61. J. Riethmuller, A. Riehle, H. Grassme, E. Gulbins, Membrane rafts in host-pathogen interactions. Biochim. Biophys. Acta 1758, 2139-2147 (2006).
62. M. Bukrinsky, D. Sviridov, Human immunodeficiency virus infection and macrophage cholesterol metabolism. J. Leukoc. Biol. 80, 1044-1051 (2006).
63. F. Lafont, F. G. van der Goot, Bacterial invasion via lipid rafts. Cell. Microbiol. 7, 613-620 (2005).
64. D. J. Hawkes, J. Mak, Lipid membrane; a novel target for viral and bacterial pathogens. Curr. Drug Targets 7, 1615-1621 (2006).
65. G. del Real, S. Jimenez-Baranda, E. Mira, R. A. Lacalle, P. Lucas, C. Gomez-Mouton, M. Alegret, J. M. Pena, M. Rodriguez-Zapata, M. Alvarez-Mon, A. C. Martinez, S. Manes, Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med. 200, 541-547 (2004).
66. A. B. van't Wout, J. V. Swain, M. Schindler, U. Rao, M. S. Pathmajeyan, J. I. Mullins, F. Kirchhoff, Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J. Virol. 79, 10053-10058 (2005).
67. T. J. Pucadyil, A. Chattopadhyay, Cholesterol: A potential therapeutic target in Leishmania infection? Trends Parasitol. 23, 49-53 (2007).
68. Y. Inoue, N. Tanaka, Y. Tanaka, S. Inoue, K. Morita, M. Zhuang, T. Hattori, K. Sugamura, Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J. Virol. 81, 8722-8729 (2007).
69. G. Krishnegowda, A. M. Hajjar, J. Zhu, E. J. Douglass, S. Uematsu, S. Akira, A. S. Woods, D. C. Gowda, Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: Cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J. Biol. Chem. 280, 8606-8616 (2005).
70. J. Zhu, G. Krishnegowda, D. C. Gowda, Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: The requirement of extracellular signal-regulated kinase, p38, c-Jun N-terminal kinase and NF-kappaB pathways for the expression of proinflammatory cytokines and nitric oxide. J. Biol. Chem. 280, 8617-8627 (2005).
71. J. Alvesalo, D. Greco, M. Leinonen, T. Raitila, P. Vuorela, P. Auvinen, Microarray analysis of a Chlamydia pneumoniae-infected human epithelial cell line by use of gene ontology hierarchy. J. Infect. Dis. 197, 156-162 (2008).
72. R. Reghunathan, M. Jayapal, L. Y. Hsu, H. H. Chng, D. Tai, B. P. Leung, A. J. Melendez, Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunol. 6, 2 (2005).
73. I. M. Pedersen, G. Cheng, S. Wieland, S. Volinia, C. M. Croce, F. V. Chisari, M. David, Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449, 919-922 (2007).
74. E. B. Speth, Y. N. Lee, S. Y. He, Pathogen virulence factors as molecular probes of basic plant cellular functions. Curr. Opin. Plant Biol. 10, 580-586 (2007).
75. J. F. Pielage, K. R. Powell, D. Kalman, J. N. Engel, RNAi screen reveals an Abl kinase-dependent host cell pathway involved in Pseudomonas aeruginosa internalization. PLoS Pathog. 4, e1000031 (2008).
76. D. Grimm, M. A. Kay, Therapeutic application of RNAi: Is mRNA targeting finally ready for prime time? J. Clin. Invest. 117, 3633-3641 (2007).
77. L. Wu, J. G. Belasco, Let me count the ways: Mechanisms of gene regulation by miRNAs and siRNAs. Mol. Cell 29, 1-7 (2008).
78. G. D. Fewell, K. Schmitt, Vector-based RNAi approaches for stable, inducible and genomewide screens. Drug Discov. Today 11, 975-982 (2006).
79. W. Filipowicz, S. N. Bhattacharyya, N. Sonenberg, Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat. Rev. Genet. 9, 102-114 (2008).
80. E. Sonkoly, M. Stahle, A. Pivarcsi, MicroRNAs and immunity: Novel players in the regulation of normal immune function and inflammation. Semin. Cancer Biol. 18, 131-140 (2008).
81. R. Krogsgaard, 2008. Santaris Pharma begins human clinical testing of the world's first medicine targeted at a human microRNA. Santaris Pharma News Release, 28 May 2008. (http://www.bioportfolio.com/biotech-news/Santaris-Pharma- 17.htm).
82. T. Shiraki, S. Kondo, S. Katayama, K. Waki, T. Kasukawa, H. Kawaji, R. Kodzius, A. Watahiki, M. Nakamura, T. Arakawa, S. Fukuda, D. Sasaki, A. Podhajska, M. Harbers, J. Kawai, P. Carninci, Y. Hayashizaki, Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc. Natl. Acad. Sci. U.S.A. 100, 15776-15781 (2003).
83. M. de Hoon, Y. Hayashizaki, Deep cap analysis gene expression (CAGE): Genome-wide identification of promoters, quantification of their expression, and network inference. Biotechniques 44 (suppl.), S627-S628 (2008).
84. A. E. Clatworthy, E. Pierson, D. T. Hung, Targeting virulence: A new paradigm for antimicrobial therapy. Nat. Chem. Biol. 3, 541-548 (2007).
85. A. Schwegmann, R. Guler, A. J. Cutler, B. Arendse, W. G. Horsnell, A. Flemming, A. H. Kottmann, G. Ryan, W. Hide, M. Leitges, C. Seoighe, F. Brombacher, Protein kinase C delta is essential for optimal macrophage-mediated phagosomal containment of Listeria monocytogenes. Proc. Natl. Acad. Sci. U.S.A. 104, 16251-16256 (2007).
86. R. Cayrol, K. Wosik, J. L. Berard, A. Dodelet-Devillers, I. Ifergan, H. Kebir, A. S. Haqqani, K. Kreymborg, S. Krug, R. Moumdjian, A. Bouthillier, B. Becher, N. Arbour, S. David, D. Stanimirovic, A. Prat, Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 9, 137-145 (2008).
87. B. Pulendran, Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199, 227-250 (2004).
88. B. Pulendran, Variegation of the immune response with dendritic cells and pathogen recognition receptors. J. Immunol. 174, 2457-2465 (2005).
89. A. M. Krieg, Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484 (2006).
90. A. G. Rothfuchs, A. Bafica, C. G. Feng, J. G. Egen, D. L. Williams, G. D. Brown, A. Sher, Dectin-1 interaction with Mycobacterium tuberculosis leads to enhanced IL-12p40 production by splenic dendritic cells. J. Immunol. 179, 3463-3471 (2007).
91. M. Yadav, J. S. Schorey, The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Blood 108, 3168-3175 (2006).
92. L. D. Sibley, Intracellular parasite invasion strategies. Science 304, 248-253 (2004).
93. R. Amino, D. Giovannini, S. Thiberge, P. Gueirard, B. Boisson, J. F. Dubremetz, M. C. Prevost, T. Ishino, M. Yuda, R. Menard, Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe 3, 88-96 (2008).
94. P. Ghosh, Process of protein transport by the type III secretion system. Microbiol. Mol. Biol. Rev. 68, 771-795 (2004).
95. N. M. Alto, F. Shao, C. S. Lazar, R. L. Brost, G. Chua, S. Mattoo, S. A. McMahon, P. Ghosh, T. R. Hughes, C. Boone, J. E. Dixon, Identification of a bacterial type III effector family with G protein mimicry functions. Cell 124, 133-145 (2006).
96. J. R. Rohde, A. Breitkreutz, A. Chenal, P. J. Sansonetti, C. Parsot, Type III secretion effectors of the IpaH family are E3 ubiquitin ligases. Cell Host Microbe 1, 77-83 (2007).
97. A. Rytkonen, J. Poh, J. Garmendia, C. Boyle, A. Thompson, M. Liu, P. Freemont, J. C. Hinton, D. W. Holden, SseL, a Salmonella deubiquitinase required for macrophage killing and virulence. Proc. Natl. Acad. Sci. U.S.A. 104, 3502-3507 (2007).
98. S. Mukherjee, G. Keitany, Y. Li, Y. Wang, H. L. Ball, E. J. Goldsmith, K. Orth, Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312, 1211-1214 (2006).
99. H. Li, H. Xu, Y. Zhou, J. Zhang, C. Long, S. Li, S. Chen, J. M. Zhou, F. Shao, The phosphothreonine lyase activity of a bacterial type III effector family. Science 315, 1000-1003 (2007).
100. T. P. Newsome, N. Scaplehorn, M. Way, SRC mediates a switch from microtubule - to actin-based motility of vaccinia virus. Science 306, 124-129 (2004).
101. A. P. Bhavsar, J. A. Guttman, B. B. Finlay, Manipulation of host-cell pathways by bacterial pathogens. Nature 449, 827-834 (2007).
102. R. Jayachandran, V. Sundaramurthy, B. Combaluzier, P. Mueller, H. Korf, K. Huygen, T. Miyazaki, I. Albrecht, J. Massner, J. Pieters, Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. Cell 130, 37-50 (2007).
103. C. L. Birmingham, D. E. Higgins, J. H. Brumell, Avoiding death by autophagy: Interactions of listeria monocytogenes with the macrophage autophagy system. Autophagy 4, 368-371 (2008).
104. C. L. Birmingham, V. Canadien, N. A. Kaniuk, B. E. Steinberg, D. E. Higgins, J. H. Brumell, Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles. Nature 451, 350-354 (2008).
105. M. Ogawa, T. Yoshimori, T. Suzuki, H. Sagara, N. Mizushima, C. Sasakawa, Escape of intracellular Shigella from autophagy. Science 307, 727-731 (2005).
106. C. E. Horak, M. Snyder, ChIP-chip: A genomic approach for identifying transcription factor binding sites. Methods Enzymol. 350, 469-483 (2002).
107. G. Robertson, M. Hirst, M. Bainbridge, M. Bilenky, Y. Zhao, T. Zeng, G. Euskirchen, B. Bernier, R. Varhol, A. Delaney, N. Thiessen, O. L. Griffith, A. He, M. Marra, M. Snyder, S. Jones, Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat. Methods 4, 651-657 (2007).
108. B. Groner, C. Borghouts, C. Kunz, Peptide aptamer libraries. Comb. Chem. High Throughput Screen. 11, 135-145 (2008).
109. R. Abes, A. A. Arzumanov, H. M. Moulton, S. Abes, G. D. Ivanova, P. L. Iversen, M. J. Gait, B. Lebleu, Cell-penetrating-peptide-based delivery of oligonucleotides: An overview. Biochem. Soc. Trans. 35, 775-779 (2007).
110. S. Karkare, D. Bhatnagar, Promising nucleic acid analogs and mimics: Characteristic features and applications of PNA, LNA, and morpholino. Appl. Microbiol. Biotechnol. 71, 575-586 (2006).
111. J. Krützfeldt, N. Rajewsky, R. Braich, K. G. Rajeev, T. Tuschl, M. Manoharan, M. Stoffel, Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
112. J. Stenvang, S. Kauppinen, MicroRNAs as targets for antisense-based therapeutics. Expert Opin. Biol. Ther. 8, 59-81 (2008).
113. C. B. Coyne, J. M. Bergelson, Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124, 119-131 (2006).
114. S. Epiphanio, S. A. Mikolajczak, L. A. Goncalves, A. Pamplona, S. Portugal, S. Albuquerque, M. Goldberg, S. Rebelo, D. G. Anderson, A. Akinc, H. P. Vornlocher, S. H. Kappe, M. P. Soares, M. M. Mota, Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection. Cell Host Microbe 3, 331-338 (2008).
115. L. Navarro, P. Dunoyer, F. Jay, B. Arnold, N. Dharmasiri, M. Estelle, O. Voinnet, J. D. Jones, A plant miRNA contributes to antibacterial resistance by repressing auxin signaling. Science 312, 436-439 (2006).
116. M. Scherr, L. Venturini, K. Battmer, M. Schaller-Schoenitz, D. Schaefer, I. Dallmann, A. Ganser, M. Eder, Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 35, e149 (2007).
117. K. D. Taganov, M. P. Boldin, K. J. Chang, D. Baltimore, NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 103, 12481-12486 (2006).
118. S. Basha, P. Rai, V. Poon, A. Saraph, K. Gujraty, M. Y. Go, S. Sadacharan, M. Frost, J. Mogridge, R. S. Kane, Polyvalent inhibitors of anthrax toxin that target host receptors. Proc. Natl. Acad. Sci. U.S.A. 103, 13509-13513 (2006).
119. R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng, D. Baltimore, MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 104, 1604-1609 (2007).
120. S. Fields, R. Sternglanz, The two-hybrid system: An assay for protein-protein interactions. Trends Genet. 10, 286-292 (1994).
121. K. M. Bushell, C. Sollner, B. Schuster-Boeckler, A. Bateman, G. J. Wright, Large-scale screening for novel low-affinity extracellular protein interactions. Genome Res. 18, 622-630 (2008).
122. M. Visintin, T. Melchionna, I. Cannistraci, A. Cattaneo, In vivo selection of intrabodies specifically targeting protein-protein interactions: A general platform for an "undruggable" class of disease targets. J. Biotechnol. 135, 1-15 (2008).
123. M. Visintin, G. A. Meli, I. Cannistraci, A. Cattaneo, Intracellular antibodies for proteomics. J. Immunol. Methods 290, 135-153 (2004).
124. S. C. Tao, C. S. Chen, H. Zhu, Applications of protein microarray technology. Comb. Chem. High Throughput Screen. 10, 706-718 (2007).